GlaxoSmithKline's $5.1 Billion Tesaro Deal Spurs M&A Hopes
(Bloomberg) -- A little more than a month after a key index of biotechnology stocks suffered their worst session in more than seven years, GlaxoSmithKline Plc delivered some much-needed good news for the sector in the form of a $5.1 billion deal.
The drugmaker's pact to pay $75 a share for cancer-focused Tesaro Inc., a more than 60 percent premium from its Friday close, is a positive for the sector and re-ignited investor hopes for deals in the space, according to analysts. SunTrust Robinson Humphrey's Peter Lawson highlighted that the deal bodes well for peer Clovis Oncology Inc., which saw shares jump by the most intraday in nearly a year and a half.
Other drugmakers who may get a tailwind after the news include those with DNA damage- response-targeting drugs like Sierra Oncology Inc., or peers working in the immuno-oncology space, including MacroGenics Inc., Incyte Corp., Array BioPharma Inc., and Deciphera Pharmaceuticals Inc, Lawson noted.
The Nasdaq Biotechnology Index, the broadest gauge of the industry's performance, remains off nearly 10 percent from a 52-week high in late August, as investors flee the risky sector amid stock market turbulence. The index gained as much as 2.3 percent in early trading, while the broader U.S. market rallied after the U.S. and China declared a truce in their trade war.
“The deal is an encouraging sign for the small-to-mid cap commercial oncology space, and we think should drive renewed interest in other commercial-stage oncology names,” RBC Capital Markets analyst Kennen MacKay wrote in a note to clients. Exelixis Inc., Puma Biotechnology Inc. and Seattle Genetics Inc. are among companies that could benefit, he noted.
Tesaro's lone marketed drug, Zejula, is expected to generate $236 million in sales this year, before rising to more than $1 billion by 2023, analyst estimates compiled by Bloomberg show. The medicine operates in a similar fashion to Clovis' Rubraca which analysts see bringing in $443 million in sales by 2022.
To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.net
To contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Steven Fromm, Morwenna Coniam
©2018 Bloomberg L.P.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
